about
Treating refractory leukemias in childhood, role of clofarabineEfficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity.A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodelingClofarabine: a new treatment option for patients with acute myeloid leukemia.Clofarabine: emerging role in leukemias.Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia.Clofarabine in the treatment of acute myeloid leukemia in older adultsAdvanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectivesOral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age.Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemiaNew nucleoside analogs for patients with hematological malignancies.Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.Clofarabine in the treatment of myelodysplastic syndromes.An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia.Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia.Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.Advanced Philadelphia chromosome positive acute lymphoblastic leukemia patients relapsed after treatment with tyrosine-kinase inhibitors: successful response to clofarabine and cyclophosphamide.Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi-center study.Use of clofarabine for acute childhood leukemia.
P2860
Q24647279-77855D23-AA1C-4007-98CF-3299DABE6FB6Q33394597-F610821D-8C1D-4B15-A4A7-14546F06989CQ33431558-56632369-4C0B-41C5-A2C0-DE3764D41A72Q33949752-D2F34253-5F29-4CC8-91E1-8C631A5F3DBEQ34159634-46B053D3-E6DA-409D-B93C-DE8EA8817C38Q34267853-283A32AD-7E0B-474F-BFEB-E8B8F3BC3B47Q34425136-B647AE8F-73B9-4C2C-AF6D-DCDC43C700A4Q34982576-F1536263-3B20-4A53-AE4E-73F5C7614E37Q35000135-847A3EBD-01A5-4EF8-BB6A-1346BA466C44Q35136616-66809711-8C5F-4533-8E82-97A5C37593B9Q36094977-D23720CF-1916-4301-B57E-F595C2B6A0B7Q36689775-75E99F05-955E-401D-99F0-D54C6A533ED5Q36776439-AA81A74E-33DC-4DC0-AB2B-7C89F4D26D3BQ36804215-EC4FA3A8-9EFA-4967-A3B9-33AE63C356CDQ36915178-C5D5FA16-8397-450C-92A8-5B32C706B251Q37140698-E59132B9-39A2-4B8A-9E73-E6758945CA4AQ37282330-A41CF612-EF0F-4EDC-ABF6-3A8AF146F60BQ37555840-0AC8E91C-E8BE-434E-ABEB-42EC17D2160DQ37841589-B17EAEE9-C91E-4225-A9AC-6C5C9DD7F6C6Q38105879-0A8EB248-7FC3-48BE-B770-C8FFB691A1A2Q38177310-7947C112-89F9-48E7-AF5A-7DAA49932757Q38285621-344E2DD9-D65C-4EBE-AB22-A04244733AE0Q39632454-990E91AD-B944-4DCE-AE70-271D5B6213C9Q40085109-FC01DE2C-1A15-4D5C-BD2A-CD72FF98965BQ41402670-32D2FB2F-2869-45C6-B2D5-59025148F91EQ41715517-F8BBB4BF-FA71-4E9B-9263-5DB0B1D9C8D9Q42574045-6157A477-8269-4EA0-9F39-205276FD9051Q42608343-14F326B3-01C6-4604-A14E-AD67EEC04601Q42737704-14485E1D-FA3A-4373-8472-F31083507D10
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Clofarabine: past, present, and future.
@ast
Clofarabine: past, present, and future.
@en
Clofarabine: past, present, and future.
@nl
type
label
Clofarabine: past, present, and future.
@ast
Clofarabine: past, present, and future.
@en
Clofarabine: past, present, and future.
@nl
prefLabel
Clofarabine: past, present, and future.
@ast
Clofarabine: past, present, and future.
@en
Clofarabine: past, present, and future.
@nl
P2093
P2860
P1433
P1476
Clofarabine: past, present, and future.
@en
P2093
Michael Wess
Varsha Gandhi
P2860
P304
P356
10.1080/10428190701545644
P577
2007-10-01T00:00:00Z